Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5053503 | 0.82 | NOS3 (0.46) | NOS3NOS1NOS2NPC1RAB9A | |
| SCHEMBL21401838 | 0.81 | PTPN1 (0.40) | NOS3NOS1NOS2NPC1RAB9A | |
| SCHEMBL17781286 | 0.79 | NPC1 (0.32) | NPC1RAB9AKDM4EHTTATM | |
| SCHEMBL30297976 | 0.78 | ATR (0.42) | NOS3NOS1NOS2NPC1RAB9A | |
| SCHEMBL16652047 | 0.78 | ATR (0.42) | NOS3NOS1NOS2NPC1RAB9A | |
| SCHEMBL22020965 | 0.75 | NOS3 (0.48) | NOS3NOS1NOS2NPC1RAB9A | |
| SCHEMBL16660696 | 0.75 | NOS3 (0.48) | NOS3NOS1NOS2LNPEPHTT | |
| SCHEMBL21879335 | 0.75 | KCNQ2 (0.43) | NOS3NOS1NOS2NPC1RAB9A | |
| SCHEMBL16651284 | 0.74 | NOS3 (0.47) | NOS3NOS1NOS2LNPEPKDM4E | |
| SCHEMBL29848830 | 0.74 | NOS3 (0.47) | NOS3NOS1NOS2LNPEPKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
| WO-2024031089-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| US-20230270734-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2023-08-31 | — | — | US | disclosed |
| US-10023592-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270734-A1 | THIENOPYRROLE COMPOUNDS | SSB, TPMT, LCP2 | NOS3 610/4885NOS1 1218/4885NOS2 725/4885 |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | NOS3 3268/4885NOS1 3486/4885NOS2 1901/4885 |
| US-10023592-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | NOS3 3903/4885NOS1 4084/4885NOS2 4130/4885 |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | NOS3 3268/4885NOS1 3486/4885NOS2 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.